Australia's most trusted
source of pharma news
Posted 21 April 2026 AM
Less restrictions and more flexibility is required to ensure treatment of multiple myeloma aligns with the latest best practices, according to a stakeholder meeting on treating the disease between the government and industry.
The Multiple Myeloma Stakeholder Meeting for Sponsors looked at issues raised in a similar meeting with clinicians and consumers last July and covered a lot of ground, most of it focused on the difficulty of giving the best treatment in response to rapid innovation while bound by tight restrictions applied to prescribing drugs subsidised by the PBS.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.